Abbott Laboratories (NYSE:ABT) Releases Q3 2026 Earnings Guidance

Abbott Laboratories (NYSE:ABT) updated its third quarter 2026 earnings guidance on Thursday. The company provided EPS guidance of 1.380-1.46 for the period, compared to the consensus estimate of 1.420. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2026 guidance to 5.450-5.60 EPS.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $89.27 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm’s 50 day simple moving average is $89.33 and its 200-day simple moving average is $102.36. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The stock has a market capitalization of $155.49 billion, a price-to-earnings ratio of 25.01, a PEG ratio of 1.53 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same quarter last year, the business earned $1.09 earnings per share. The firm’s revenue was up 7.8% on a year-over-year basis. Analysts expect that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of recent analyst reports. Argus cut their price objective on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Daiwa Securities Group cut shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research note on Wednesday, April 22nd. Leerink Partners reduced their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. JPMorgan Chase & Co. dropped their target price on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Finally, Sanford C. Bernstein reduced their price target on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $117.61.

Insiders Place Their Bets

In other news, CFO Philip P. Boudreau purchased 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The shares were bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by company insiders.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Analysts expect Abbott’s upcoming Q2 results to show healthy revenue and earnings growth, supported by strong performance in Diagnostics, Devices and Emerging Pharmaceutical/EPD segments. Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition
• Positive Sentiment: Coverage around Abbott’s cancer diagnostics strategy highlights longer-term growth potential, with management continuing to invest in improving tests and expanding the business after the Exact Sciences acquisition. Abbott’s cancer diagnostics vision: ‘There’s always a hunger to make these tests better’
• Positive Sentiment: Analysts are still recommending investors retain Abbott shares for now, citing emerging-market pharmaceutical growth and continued innovation in nutrition as potential supports for the stock. Reasons to Retain Abbott Stock in Your Portfolio for Now
• Neutral Sentiment: Market commentary says Abbott is one of the names investors are watching as earnings season begins, but the article is mainly a watchlist note rather than fresh company-specific news. UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday
• Neutral Sentiment: Another brief market note also flags Abbott ahead of earnings, reinforcing that the stock is being traded around the upcoming results. UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday
• Negative Sentiment: Risks remain from macro pressure and foreign exchange swings, which could weigh on results even if core business trends stay healthy. Reasons to Retain Abbott Stock in Your Portfolio for Now
• Negative Sentiment: Nutrition remains a drag in the near term, and some coverage notes that this segment could limit upside if other divisions do not fully offset it. Abbott’s Q2 Earnings on Deck: How Should You Play the Stock Now?

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ABT. Intesa Sanpaolo Wealth Management purchased a new position in Abbott Laboratories in the 4th quarter valued at approximately $29,000. SWAN Capital LLC boosted its holdings in Abbott Laboratories by 53.1% in the fourth quarter. SWAN Capital LLC now owns 300 shares of the healthcare product maker’s stock valued at $38,000 after purchasing an additional 104 shares during the period. Turning Point Benefit Group Inc. acquired a new position in Abbott Laboratories during the 3rd quarter worth $39,000. Wealth Watch Advisors INC increased its holdings in Abbott Laboratories by 121.6% during the 4th quarter. Wealth Watch Advisors INC now owns 359 shares of the healthcare product maker’s stock worth $45,000 after purchasing an additional 197 shares during the period. Finally, Swiss RE Ltd. purchased a new stake in Abbott Laboratories during the 4th quarter worth about $49,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.